(Total Views: 602)
Posted On: 08/24/2020 5:50:31 PM
Post# of 153898
Re: Shelly2626 #52001
Someone pretty up the font, and take a picture. It should be short enough to fit:
* Safe to use compared to SOC
* Most mild to moderate patients will resolve their symptoms with supportive treatment by day 14. Thus this is the most difficult group to achieve statistical significance.
* But compared to standard of care (SOC), by day 3, leronlimab showed faster clinical improvement, thus shortening hospitalization and saving the healthcare system, hospital and patients $$$. We expect that by day 14 there is no difference between leronlimab and SOC because people get better on their own in this group.
* eIND from Montefiore showed
1. normalization of CD4/CD8 ratios
2. decrease of IL-6 and RANTES by day 3
3. decrease in viral loads by day 7 and zero viral load by day 14
So to summarize:
1. Save $$$
2. Safe drug to use
3. Get people out of the hospital quicker before they progress into S/C group
4. restoration of immune system
* Safe to use compared to SOC
* Most mild to moderate patients will resolve their symptoms with supportive treatment by day 14. Thus this is the most difficult group to achieve statistical significance.
* But compared to standard of care (SOC), by day 3, leronlimab showed faster clinical improvement, thus shortening hospitalization and saving the healthcare system, hospital and patients $$$. We expect that by day 14 there is no difference between leronlimab and SOC because people get better on their own in this group.
* eIND from Montefiore showed
1. normalization of CD4/CD8 ratios
2. decrease of IL-6 and RANTES by day 3
3. decrease in viral loads by day 7 and zero viral load by day 14
So to summarize:
1. Save $$$
2. Safe drug to use
3. Get people out of the hospital quicker before they progress into S/C group
4. restoration of immune system
(0)
(0)
